Safety and Immunogenicity of Inactivated Whole Virion COVID-19 Vaccine CoviVac in Clinical Trials in 18–60 and 60+ Age Cohorts
暂无分享，去创建一个
G. Ignatyev | L. Kozlovskaya | V. Akimkin | L. Gmyl | E. Tivanova | A. V. Kalenskaya | A. Ploskireva | A. Ishmukhametov | Y. V. Rogova | I. Gordeychuk | V. I. Kuzubov | A. Piniaeva | V. Volok | A. Shishova | A. Kovpak | Y. Ivin | L. P. Antonova | E. Bayurova | E. Ipatova | A. Siniugina | N. V. Yagovkina | Ksenia A. Subbotina | E. Shustova | N. A. Korotina | S. E. Sotskova | M. Dodina | I. Solovjeva | K. Zakharov | Anastasia K. Korduban | Alla S. Zhitkevich | Daria V. Avdoshina | Yu. I. Ulitina | Rostislav D. Theodorovich | Dmitry I. Vovk | Marina V. Alikova | Anna A. Kataeva | Larissa Y. Kondrasheva | Konstantin A. Chernov | E. A. Korduban